

ITM and SpiroChem Announce Strategic Discovery Collaboration to Expand ITM's Radiopharmaceutical Pipeline

Garching / Munich, Germany, and Basel, Switzerland, September 8, 2026 – [ITM Isotope Technologies Munich SE \(ITM\)](#), a leading radiopharmaceutical biotech company, and [SpiroChem AG](#) (SpiroChem), a Swiss Partner Research Organization specializing in complex medicinal chemistry, today announced a strategic drug discovery collaboration to advance a novel radiopharmaceutical candidate for ITM's pipeline. Additional details regarding the program target and financial terms of the collaboration have not been disclosed.

Under the collaboration, the parties will leverage their complementary capabilities by combining SpiroChem's advanced drug discovery platforms, macrocycle libraries and screening engine with ITM's radiopharmaceutical development expertise to discover high-affinity binders and advance a potential first-in-class radiopharmaceutical candidate. The focus is on the development of a small molecule targeting agent directed at a cancer-associated marker in a solid tumor indication with limited treatment options. SpiroChem will lead hit identification and optimization activities, while ITM will contribute its expertise in radiopharmaceutical research and development spanning preclinical through clinical stages.

"Our agreement with SpiroChem gives us access to new drug discovery capabilities and a differentiated technology platform. This agreement reflects our ongoing commitment to strategically grow our radiopharmaceutical pipeline by pursuing novel biological targets with the potential to address significant unmet medical needs. Through the addition of this targeting program, we will further enhance the breadth of our portfolio and expand our ability to pursue new, promising opportunities in precision oncology for patients living with hard-to-treat cancers," said **Dr. Andrew Cavey, chief executive officer of ITM**.

This collaboration is intended to broaden the scope of ITM's pipeline, which currently includes 13 radiopharmaceutical drug candidates spanning preclinical development through Phase 3.

Thomas Fessard, PhD, CEO and co-founder of SpiroChem, added, "This program reflects our approach to working as a true discovery partner on complex programs where chemistry plays a central role in success. By bringing our proprietary macrocycle libraries, screening engine and design platforms to bear on ITM's deep radiopharmaceutical pipeline, we aim to identify and progress high-quality chemical matter suitable for targeted radionuclide therapies. We are particularly excited to contribute across the full design-make-test cycle, and to do so in close collaboration with ITM's highly experienced teams."

About ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

About SpiroChem AG

SpiroChem AG is a Swiss Partner Research Organization (PRO) and ETH Zürich spin-off specializing in complex medicinal chemistry and integrated drug discovery. The company supports pharmaceutical, biotechnology, and research organizations in the design and development of challenging molecules, including macrocycles, peptides, and other beyond-Rule-of-5 compounds.

SpiroChem combines proprietary platforms, such as its SpiroQuest macrocycle library and Hercules+ discovery platform, with advanced design, synthesis, and optimization capabilities to enable the discovery of high-quality chemical matter. Its platform has been further strengthened through the integration of Cyclenium Pharma technologies, expanding its capabilities in peptide and macrocycle-based discovery.

Through its integrated discovery model, SpiroChem orchestrates internal and external capabilities to support programs from early discovery through to development candidate. Headquartered in Basel, Switzerland, with additional operations in Montreal, Canada, SpiroChem serves clients globally across a broad range of therapeutic areas and modalities.

ITM Contact

Corporate Communications

Kathleen Noonan/Julia Westermeir

Phone: +49 89 329 8986 1500

Email: communications@itm-radiopharma.com

Investor Relations

Ben Orzelek

Phone: +49 89 329 8986 1009

Email: investors@itm-radiopharma.com

SpiroChem AG Contact

Email: contact@spirochem.com

Website: www.spirochem.com